在全球生物市场利用特有技术积极开展事业
细胞批量培养技术 + 质量管理技术
兼具两种核心技术的企业
获得主导新药开发市场的
主要国家的专利
利用专利技术开拓国际市场
知识产权
我们通过建立知识产权保护核心技术
| 技术名称 | 申请国家 | 申请·注册号 | 申请·登记日期 |
|---|---|---|---|
| 用于检测细胞硫醇水平的 实时成像传感器 |
韩国 | 10-1862581 | 2018. 05. 24 |
| 美国 | 10.215.757B2 | 2019. 02. 26 | |
| 韩国 | 10-1983803 | 2019. 05. 23 | |
| 美国 | 10.620.215 | 2020. 04. 14 | |
| 细胞器内谷胱甘肽检测用 实时荧光成像传感器及其制造方法 |
韩国 | 10-2133794 | 2020. 07. 08 |
| 加拿大（申请） | 3.072.434 | 2020. 02. 07 | |
| 澳大利亚（申请） | 2018320601 | 2020. 02. 19 | |
| 美国（申请） | 16/640717 | 2020. 02. 20 | |
| 欧洲（申请） | 18848372.1 | 2020. 02. 21 | |
| 中国（申请） | 201880054675.0 | 2020. 02. 21 | |
| 印度（申请） | 202017007994 | 2020. 02. 25 | |
| 日本（申请） | 2020-511502 | 2020. 02. 19 | |
| 内质网内谷胱甘肽检测用 实时荧光成像传感器及其使用方法 |
韩国 | 10-2019-0178260 | 2019. 12. 30 |
Gene Biomarker
| 技术名称 | 申请国家 | 申请·注册号 | 申请·登记日期 |
|---|---|---|---|
| 基于 FreSHtracer 分离的细胞 基因配置文件的应用 |
PCT | PCT/KR 2018/008239 | 2018. 07. 20 |
Stem Cell Therapy
| 技术名称 | 申请国家 | 申请·注册号 | 申请·登记日期 |
|---|---|---|---|
| 用于治疗血小板减少症的组合物 | 韩国 | 10-2021-0063975 | 2021. 05. 18 |
| 用于评估干细胞特性的 基因标记及其用途 |
韩国 | 10-2020-0180455 | 2020. 12. 22 |
Cell Quality Control
| 技术名称 | 申请国家 | 申请·注册号 | 申请·登记日期 |
|---|---|---|---|
| 通过实时检测谷胱甘肽， 提高治疗用细胞质量的方法 |
韩国 | 10-2119714 | 2020. 06. 01 |
| 欧洲（申请） | 18883520.1 | 2020. 05. 27 | |
| 中国（申请） | 201880077266.2 | 2020. 05. 28 | |
| 日本（申请） | 2020-546264 | 2020. 05. 27 | |
| 美国（申请） | 16/767985 | 2020. 05. 28 | |
| 通过实时检测谷胱甘肽， 检测治疗用细胞质量的方法 |
韩国 | 10-2145929 | 2020. 08. 12 |
| 美国（申请） | 16/768014 | 2020. 05. 28 | |
| 欧洲（申请） | 18884812.1 | 2020. 05. 27 | |
| 中国（申请） | 201880077236.1 | 2020. 05. 28 | |
| 日本（申请） | 2020-546265 | 2020. 05. 27 |
发表
接连在知名学术期刊上发表了研究成果
Development Technology and mesenchymal stem cells : Lim et al., Glutathione dynamics determine the therapeutic efficacy of mesenchymal stem cells for graft-versus-host disease via CREB1-NRF2 pathway, Science Advances (2020), 6
Glutathione (GSH), the most abundant nonprotein thiol functioning as an antioxidant, plays critical roles in maintaining
the core functions of mesenchymal stem cells (MSCs), which are used as a cellular immunotherapy for
graft-versus-host disease (GVHD). However, the role of GSH dynamics in MSCs remains elusive. Genome-wide
gene
expression profiling and high-throughput live-cell imaging assays revealed that CREB1 enforced the GSH-recovering
capacity (GRC) of MSCs through NRF2 by directly up-regulating NRF2 target genes responsible for GSH synthesis
and redox cycling. MSCs with enhanced GSH levels and GRC mediated by CREB1-NRF2 have improved
self-renewal, migratory, anti-inflammatory, and T cell suppression capacities. Administration of MSCs overexpressing
CREB1-NRF2 target genes alleviated GVHD in a humanized mouse model, resulting in improved survival,
decreased weight loss, and reduced histopathologic damages in GVHD target organs. Collectively, these findings
demonstrate the molecular and functional importance of the CREB1-NRF2 pathway in maintaining MSC GSH dynamics,
determining therapeutic outcomes for GVHD treatment.
the core functions of mesenchymal stem cells (MSCs), which are used as a cellular immunotherapy for
graft-versus-host disease (GVHD). However, the role of GSH dynamics in MSCs remains elusive. Genome-wide
gene
expression profiling and high-throughput live-cell imaging assays revealed that CREB1 enforced the GSH-recovering
capacity (GRC) of MSCs through NRF2 by directly up-regulating NRF2 target genes responsible for GSH synthesis
and redox cycling. MSCs with enhanced GSH levels and GRC mediated by CREB1-NRF2 have improved
self-renewal, migratory, anti-inflammatory, and T cell suppression capacities. Administration of MSCs overexpressing
CREB1-NRF2 target genes alleviated GVHD in a humanized mouse model, resulting in improved survival,
decreased weight loss, and reduced histopathologic damages in GVHD target organs. Collectively, these findings
demonstrate the molecular and functional importance of the CREB1-NRF2 pathway in maintaining MSC GSH dynamics,
determining therapeutic outcomes for GVHD treatment.